The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.19
Bid: 0.18
Ask: 0.20
Change: 0.00 (0.00%)
Spread: 0.02 (11.111%)
Open: 0.19
High: 0.00
Low: 0.00
Prev. Close: 0.19
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: De La Rue Down As CEO Exits And Profit Falls

Thu, 30th May 2019 10:33

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - LOSERS----------National Grid, down 4.7%, Marks & Spencer, down 4.3%. The stocks went ex-dividend meaning new buyers no longer qualify for the latest payout. ----------Johnson Matthey, down 3.5%. The speciality chemicals firm upped its annual payout following a sharp increase in profit but said growth will be slower next year due to plans for significant investment. "We anticipate that these investments for growth and efficiency will lead to a slightly lower margin than in 2018-19," the company said. Johnson Matthey reported 53% growth in pretax profit to GBP488 million in the financial year that ended on March 31 compared to GBP320 million reported the year earlier, as revenue rose 4.6% to GBP10.75 billion from GBP10.27 billion. Profit was slightly short of market expectations. According to company-compiled consensus figures for financial 2019, pretax profit was expected to jump 56% to GBP500.7 million. Johnson Matthey declared a final dividend of 62.25 pence a share, taking the total payout for the year to 85.5p, up 6.9% from 80.0p paid the year before. Looking ahead, Johnson Matthey said it expects foreign exchange movements in the financial year to the end of March 2020 to hurt sales and underlying operating profit by GBP6 million and GBP2 million, respectively.----------FTSE 250 - WINNERS----------FirstGroup, up 5.5%. The transport operator unveiled a new strategy which will see the sale of the transport operator's North American intercity coach operation, Greyhound, as well as separation of its UK bus business, First Bus. The company said it has started the sale process for Greyhound as the unit has "limited synergies" with the rest of the company's operations. For the same reason, FirstGroup plans to separate First Bus from its UK operations. Going ahead, North America will be the firm's core market with emphasis on First Student and First Transit, which together generated 60% of group operating profit in 2019 and "have the greatest potential to generate sustainable value and growth over time". Separately, the company reported a narrowed pretax loss for the year ended March to GBP97.9 million from GBP326.9 million. Revenue for the year rose 11% to GBP7.13 billion from GBP6.40 billion. Looking ahead, FirstGroup said it expects to deliver revenue growth and financial progress in its Road divisions in financial 2020, with adjusted earnings guided "broadly in line with expectations". Spreadex analyst Connor Campbell said: "Beyond replacing the CEO and board, this basically ticks off most of the demands Coast Capital had been making, and was clearly popular with investors,"----------Tullow Oil, up 3.5%. Goldman Sachs promoted the oil and gas company to its Conviction Buy List.----------FTSE 250 - LOSERS----------Computacenter, down 1.7%. The stock went ex-dividend.----------Babcock International, down 1.6%. Goldman Sachs downgraded the engineering services firm to Neutral from Conviction Buy. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Nuformix, up 37%. The pharmaceutical development company reported positive results in its clinical study of NXP001. The company explained that NXP001 is being developed as a treatment for chemotherapy-induced nausea and vomiting, occurring in a third of cancer patients worldwide. In a pilot study conducted among healthy subjects, Nuformix's cocrystal-based formulation demonstrated bioequivalence to Merck's EMEND, the currently used treatment for nausea and vomiting in chemotherapy, both in terms of peak and overall exposure. The positive results allow Nuformix to receive a final GBP2 million milestone payment form its Chinese licensing partner, Newsummit Biopharma, which has started product registration in China.----------BigDish, up 15%. The online reservation platform said it is now ready to start the larger UK roll out of its restaurant reservation app. The company's BigDish app is expected to go live in Brighton and Reading on June 7, following the successful launch in Swindon and Taunton. The app allows restaurant-goers to book a table and receive discounts. As it rolls the service out nationwide, Big Dish has divided the UK into ten territories. Each territory will have one manager with the exception of London, which will have three. BigDish expects the managers recruitment process to take between three and four months. The company now has over 150 restaurants on its platform, most of which independent. It said its roll out plans will initially target independent and smaller restaurant groups. ----------OTHER MAIN MARKET AND AIM - LOSERS----------De La Rue, down 31%. The banknote printer proposed a restructuring, after annual profit fell sharply and in preparation for the expiration of the company's UK passport contract. In addition, De La Rue said Martin Sutherland has agreed to step down as chief executive as soon as his successor is in place. The company has already commenced the recruitment process, it said. Pretax profit for the financial year ended March 30 dropped to GBP25.5 million from GBP113.6 million a year earlier, as operating expenses jumped to GBP533.3 million from GBP370.9 million. De La Rue declared a final dividend of 16.7 pence a share, unchanged from the prior year. This would make a full year payout of 25.0p per share, also unchanged. De La Rue proposed a reorganisation that is aimed at creating better strategic focus and greater efficiency, with a cost-cutting programme that will deliver in excess of GBP20 million annual savings by 2022. De La Rue intends to restructure its operations into two divisions: Authentication and Currency. ----------

More News
25 Oct 2019 12:27

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Nuformix Confirms Japan, Asia Licencing Talks As Shares Surge

Read more
10 Sep 2019 13:47

Nuformix Chief Financial Officer Kirk Siderman-Wolter Resigns Abruptly

(Alliance News) - Pharmaceutical company Nuformix PLC on Tuesday said Chief Financial Officer and Senior Independent Non-Executive Director Kirk Siderman-Wolter has resigned with immediate company

Read more
9 Sep 2019 11:25

Nuformix, Ebers Tech File Patent For Cannabinoid Cocrystals

(Alliance News) - Pharmaceutical company Nuformix PLC on Monday said it and partner Ebers Tech Inc have filed the first patent in relation to cannabinoid cocrystals.The patented cannabinoid

Read more
6 Sep 2019 12:17

Nuformix Hires Cambridge Interstitial Lung Disease Unit Lead Clinician

(Alliance News) - Nuformix PLC said on Friday it has appointed Muhunthan Thillai to its scientific advisory board with immediate effect.Thillai is the lead clinician for the Cambridge Lung

Read more
18 Jul 2019 11:16

Nuformix Annual Loss Narrows As Revenue Jumps On NXP001 Progress

(Alliance News) - Nuformix PLC on Thursday said its revenue multiplied in its most recently-ended financial year as it has secured its first licensing income from NXP001.NXP001 is one of in

Read more
30 May 2019 10:14

Nuformix Shares Jump On Positive NXP001 Clinical Study Results

LONDON (Alliance News) - Shares in Nuformix PLC surged on Thursday as the company reported positive results in its clinical study of NXP001.Nuformix shares were trading 30% higher at 13.50

Read more
9 Apr 2019 11:25

Nuformix inks cannabinoid therapeutics deal with Ebers Tech

(Sharecast News) - Pharmaceutical development company Nuformix has inked an agreement for cannabinoid therapeutics development, licensing and commercialisation with Canadian outfit Ebers Tech.

Read more
9 Apr 2019 10:46

WINNERS & LOSERS SUMMARY: 7digital Warns Of Need For Capital Raise

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Anglo up -

Read more
22 Mar 2019 08:50

Nuformix Doses First Patient In NXP001 Anti-Nausea Drug Trial

LONDON (Alliance News) - Nuformix PLC on Friday said it has begun clinical studies for its anti-nausea drug NXP001 and dosed its first patient.Shares in Nuformix were down 4.6% at 2.10 on a

Read more
27 Feb 2019 10:48

MHRA gives go-ahead to Nuformix for human studies

(Sharecast News) - Pharmaceutical development company Nuformix has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to begin human pharmacokinetics studies for its lead asset, NXP001, it announced on Wednesday.

Read more
3 Dec 2018 09:53

Nuformix Reports Positive Results From NXP002 Pre-Clinical Trial

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC on Monday reported positive results from its completed NXP002 fibrosis programme pre-clinical trial for the treatment of a of

Read more
27 Nov 2018 10:04

Nuformix Expands NXP001 Agreement With Additional Pre-Clinical Study

LONDON (Alliance News) - Pharmaceutical development firm Nuformix PLC said on Tuesday it has expanded its current licensing agreement with partner Newsummit Biopharma for the development of cancer

Read more
14 Sep 2018 10:17

Nuformix Rises As NXP001 Passes "Major" Pre-Clinical Milestone

LONDON (Alliance News) - Shares in pharmaceutical firm Nuformix PLC rose Friday it has received a GBP500,000 payment after its NXP001 product reached a pre-clinical milestone.Nuformix was a

Read more
12 Sep 2018 16:00

UK Shareholder Meetings Calendar - Next 7 Days

Thursday 13 SeptemberBahamas PetroleumFlybe GroupBetter Capital PCCWorldwide 14 UK 17

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.